Real-world effectiveness of initial antiviral regimens in children with chronic hepatitis B: an age-stratified cohort study.

ABSTRACT:

Background

Interferons (IFN-α) and nucleos(t)ide analogues (NAs) are currently the primary treatment options for children with chronic hepatitis B (CHB), but the efficacy of different initial antiviral regimens in children with different ages remains unclear.

Methods

This study included 483 treatment-naïve children with CHB who received initial antiviral therapy at Hunan Children's Hospital between June 2015 and November 2023. According to the initial 24-week regimens, patients were divided into (Peg) IFN-α monotherapy, NAs monotherapy, and combination therapy groups, and stratified by age of treatment initiation (1-7 years vs. ≥ 7 years). The study outcome was HBsAg loss. Propensity score matching (PSM) was used to adjust for confounding factors, and a sensitivity analysis

SUBMITTER: Li S 

PROVIDER: S-EPMC12418834 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature